Drugmakers are expected to increase list prices on more than 1,000 medicines this year, and already raised the prices on ...

Regeneron, maker of the blockbuster ophthalmology medicine Eylea, has acquired an ocular biotech, the large biopharma ...

Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...

Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.

Nine-figure financings dominated biotech's venture funding landscape, with 96 such rounds tallied by Endpoints News. The bevy of megarounds drowned out smaller ...